Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA,
Curr Infect Dis Rep. 2011 Feb;13(1):102-7. doi: 10.1007/s11908-010-0143-y.
A vaccine against recurrent vulvovaginal candidiasis (RVVC) would benefit a large number of women who suffer from this debilitating syndrome. To date, several antigen formulations have been tested with modest results. In this article, we review the latest vaccine study reported in the literature. The candidate is a β-glucan conjugate administered with a human compatible adjuvant. Results in a mouse model of vaginitis were again modest for protection. However, the study included live animal imaging to quantify fungal burden; animals were challenged with a Candida strain carrying a gene encoding a glycophosphatidylinositol (GPI)-linked cell wall protein and luciferase. Fungal burden was expressed as photons following substrate administration. Protection appeared to be mediated by β-glucan antibodies. Although modest protection was observed, the imaging system was less variable than semi-quantitative plate counts of vaginal lavage fluid. Despite these advances in evaluating protection, a vaccine candidate against RVVC worthy of clinical testing remains elusive.
一种用于复发性外阴阴道念珠菌病（RVVC）的疫苗将使许多患有这种使人虚弱的综合征的女性受益。迄今为止，已经测试了几种抗原制剂，但结果并不理想。在本文中，我们回顾了文献中报道的最新疫苗研究。候选疫苗是一种与人类相容佐剂联合使用的β-葡聚糖缀合物。在阴道炎症的小鼠模型中，保护效果再次不太理想。然而，该研究包括活体动物成像来定量真菌负荷；动物受到携带编码糖基磷脂酰肌醇（GPI）连接细胞壁蛋白和荧光素酶的基因的念珠菌菌株的挑战。真菌负荷在底物给药后用光子表示。保护似乎是由β-葡聚糖抗体介导的。尽管观察到适度的保护，但成像系统比阴道冲洗液的半定量平板计数的变异性更小。尽管在评估保护方面取得了这些进展，但一种值得进行临床测试的 RVVC 疫苗候选物仍然难以捉摸。
